Filtered By:
Procedure: Heart Valve Surgery
Countries: Japan Health
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 28 results found since Jan 2013.
Discrepancy of Aortic Valve Area Measurements by Doppler vs. Biplane Stroke Volume Measurements and Utility of Combining the Different Areas in Aortic Valve Stenosis - The Asian Valve Registry.
CONCLUSIONS: Discrepancy in AVAI by Doppler vs. biplane method was significantly more pronounced with increased LV outflow tract flow velocity, shorter height, lower weight, older age and smaller LV cavity dimensions. Combining the AVAIs enabled mutual and incremental value in predicting events.
PMID: 33208592 [PubMed - as supplied by publisher]
Source: Circulation Journal - November 19, 2020 Category: Cardiology Authors: Iwataki M, Kim YJ, Park SW, Ling LH, Yu CM, Okura H, Ha JW, Hozumi T, Tanaka H, Izumi C, Yuasa T, Song JK, Otsuji Y, Sohn DW Tags: Circ J Source Type: research
FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease who have...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with congenita...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
EdoxabaN Versus standard of care and theIr effectS on clinical outcomes in pAtients havinG undergonE Transcatheter Aortic Valve Implantation in Atrial Fibrillation—Rationale and design of the ENVISAGE-TAVI AF trial
Publication date: November 2018Source: American Heart Journal, Volume 205Author(s): Nicolas M. Van Mieghem, Martin Unverdorben, Marco Valgimigli, Roxana Mehran, Eric Boersma, Usman Baber, Christian Hengstenberg, Minggao Shi, Cathy Chen, Shigeru Saito, Roland Veltkamp, Pascal Vranckx, George D. DangasTranscatheter aortic valve implantation, also called transcatheter aortic valve replacement (TAVR), is the treatment of choice for patients with severe aortic stenosis and intermediate to high operative risk. A significant portion of TAVR patients have atrial fibrillation (AF) requiring chronic oral anticoagulation. In moderate...
Source: American Heart Journal - August 30, 2018 Category: Cardiology Source Type: research
Differences in Flow-Gradient Patterns Between Severe Bicuspid Aortic Stenosis and Severe Tricuspid Aortic Stenosis - Mechanistic Insight From Multimodal Imaging.
CONCLUSIONS: Flow-gradient patterns in bicuspid AS differ from those of tricuspid AS and are associated with the structural and functional characteristics of the aorta.
PMID: 31787664 [PubMed - as supplied by publisher]
Source: Circulation Journal - November 29, 2019 Category: Cardiology Authors: Kim D, Shim CY, Kim YJ, Nam K, Hong GR, Lee SH, Lee S, Ha JW Tags: Circ J Source Type: research
Registry of antithrombotic therapy in atrial fibrillation patients with bioprosthetic valves: A retrospective observational study.
CONCLUSIONS: In a current real-world setting in Japan, warfarin was the most commonly used treatment in AF patients with bioprosthetic valves, but there was an increasing trend of DOAC-treated patients. Further investigations are needed to confirm the efficacy and safety of DOAC in patients with bioprosthetic valves.
PMID: 32156512 [PubMed - as supplied by publisher]
Source: Journal of Cardiology - March 6, 2020 Category: Cardiology Authors: Izumi C, Miyake M, Amano M, Kitai T, Obayashi Y, Takegami M, Kimura T, Sugio K, Matsumoto T, Nishimura K, Furukawa Y Tags: J Cardiol Source Type: research
Clinical Outcomes in Patients Treated With a Repositionable and Fully Retrievable Aortic Valve - REPRISE Japan Study.
CONCLUSIONS: Data from REPRISE Japan confirm the safety and efficacy of the LOTUS Valve when used in Japanese clinical practice.
PMID: 33191317 [PubMed - as supplied by publisher]
Source: Circulation Journal - November 14, 2020 Category: Cardiology Authors: Saito S, Hayashida K, Takayama M, Goto T, Ihlberg L, Sawa Y Tags: Circ J Source Type: research
Edoxaban vs. Vitamin K Antagonist for Atrial Fibrillation After Transcatheter Aortic Valve Replacement in Japanese Patients - A Subanalysis of the ENVISAGE-TAVI AF Trial
CONCLUSIONS: In Japanese patients with AF after successful TAVR, edoxaban and VKA treatment have similar safety and efficacy profiles.PMID:35965066 | DOI:10.1253/circj.CJ-22-0093
Source: Circulation Journal - August 14, 2022 Category: Cardiology Authors: Yusuke Watanabe Kentaro Hayashida Masanori Yamamoto Futoshi Yamanaka Kazumasa Yamasaki Toru Naganuma Yohei Ohno Masahiro Yamawaki Nobuyuki Morioka Kazuki Mizutani Norio Tada Hiroshi Ueno Hidetaka Nishina Masaki Izumo Yoshifumi Nakajima Kenji Ando Kensuke Source Type: research
First Clinical Trial of a Self-Expandable Transcatheter Heart Valve in Japan in Patients With Symptomatic Severe Aortic Stenosis.
Conclusions: This is the first study to evaluate a self-expandable TAV in a Japanese patient population. The data show successful achievement of the study's primary objective and demonstrate the functional and anatomical effectiveness of the MDT-2111 TAV system.
PMID: 24662399 [PubMed - as supplied by publisher]
Source: Circulation Journal - March 21, 2014 Category: Cardiology Authors: Sawa Y, Saito S, Kobayashi J, Niinami H, Kuratani T, Maeda K, Kanzaki H, Komiyama N, Tanaka Y, Boyle A, Zhang A, Moore BJ, de Medeiros R, for the MDT-2111 Japan Investigators Tags: Circ J Source Type: research
Scientists discover new type of immune cells that are essential for forming heart valves
UCLA researchers have identified for the first time the origin of an immune cell that plays a critical role in the formation of healthy heart valves. The findings could pave the way for new treatments for heart valve disorders, which can be caused by congenital defects, aging or disease.Their study, led by Dr. Atsushi “Austin” Nakano, a UCLA associate professor of molecular, cell and developmental biology and member of theEli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA, was published in the journal Developmental Cell.Building on previous research by Nakano, which showed that the embr...
Source: UCLA Newsroom: Health Sciences - February 21, 2019 Category: Universities & Medical Training Source Type: news
Which Patients Are Candidates for Minimally Invasive Mitral Valve Surgery? - Establishment of Risk Calculators Using National Clinical Database.
CONCLUSIONS: We developed risk calculator formulas using risk factors associated with both operative mortality and composite outcome. The present risk calculator formula is useful for patient selection and may influence future applications for this procedure.
PMID: 31257312 [PubMed - as supplied by publisher]
Source: Circulation Journal - June 28, 2019 Category: Cardiology Authors: Nishi H, Miyata H, Motomura N, Takahashi T, Sawa Y, Takamoto S, Japan Cardiovascular Surgery Database Organization Tags: Circ J Source Type: research
Clinical outcome after surgical aortic valve replacement in low-risk Japanese patients with severe aortic stenosis
AbstractTwo randomized control trials demonstrated that transcatheter aortic valve implantation was associated with 1 –2 year clinical outcomes comparable or even superior to surgical aortic valve replacement (SAVR) in low surgical risk patients with severe aortic stenosis (AS). However, no previous study has reported the clinical outcomes after SAVR in Japanese patients with low surgical risk. From 3815 consecu tive patients enrolled in the CURRENT AS registry, we retrieved 220 patients who underwent SAVR in reference to the inclusion and exclusion criteria of the PARTNER 3 trial. Age and surgical risk score in the cur...
Source: Cardiovascular Intervention and Therapeutics - March 12, 2020 Category: Cardiology Source Type: research
Rationale, Design, and Baseline Characteristics of the BioProsthetic Valves with Atrial Fibrillation (BPV-AF) Study
ConclusionPatients enrolled into this study are typical of the wider Japanese AF/BPV population in terms of age and clinical history. Future data accruing from the observational period will contribute to future treatment recommendations and guide therapeutic decisions in patients with BPV and AF.Trial registrationClinicalTrials.gov Identifier: UMIN000034485
Source: Cardiovascular Drugs and Therapy - July 23, 2020 Category: Cardiology Source Type: research
